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THERMAL ABLATION ALTERS THE TUMOR MICROENVIRONMENT ACTIVATING A 
ROBUST IMMUNE RESPONSE. 
Matthew T Campbell, M.D. 
Advisor Professor: Padmanee Sharma, M.D Ph.D 
Ablation techniques including radiofrequency ablation (RFA) and cryoablation have been 
shown to influence the immune system in animal models.  Rare abscopal events, a distant 
metastatic response to a local procedure, have been observed in humans following both RFA and 
cryoablation.  These rare observations have led to interest in further defining the impact of 
ablation procedures on the immune signature in the tumor microenvironment and in the systemic 
circulation.    
Retrospectively 9 patients with nephrectomy alone (control) were compared to 16 
patients treated with ablation.  Gene microarray analysis and immunohistochemistry (IHC) for 
presence of immune cell subtypes were performed on the tissue samples.  Prospectively, blood 
was collected from patients 13 patients who underwent renal ablation for renal cell carcinoma for 
stage T1a (less than 4cm) at baseline and at day 1, day 28, and 6 months following the 
procedure.  The blood was assessed by flow cytommetry and plasma cytokine levels at each time 
point following the procedure.  GraphPad Prism version 6 was used to perform statistical 
analysis.  The student’s t-test, Kruskal Wallis test, Friedman’s test, and Dunn’s multiple 
comparisons test were used when appropriate. 
IHC identified a significant difference (p=0.04) in programmed cell death 1 (PD-1) levels 
in the tumor invasive margin when comparing control to ablated tumors, while other tumor stains 
showed no significant differences between the two groups.  Gene microarray analysis comparing 
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control patients to three ablation specimens after RFA found significant differential gene 
expression in pathways and processes involving the immune system.  Flow cytommetry markers 
consistent with previously characterized T regulatory populations of immune cell were found to 
trend upward at 24 hours following ablation compared to baseline levels.  Cytokine analysis 
revealed elevated levels of IL-6 that increased at day 1 and returned toward baseline by day 28.   
RFA and cryoablation cause local tissue destruction and an inflammatory immune 
response that can be detected by gene microarray.  Significant changes in tissue IHC, plasma 
cytokine levels, and immune cell populations in peripheral blood flow cytommetry analysis were 
not detected.  
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I. Background:  
Thermal ablation refers to interventional procedures that use extreme temperature to 
cause local tissue damage.  The two most common procedures employing extreme temperature 
consist of radiofrequency ablation (RFA) and cryoablation.  Both procedures introduce a metal 
probe into a tumor using direct visual or imaging guidance with either ultrasound or computated 
tomography (CT) guidance.  Using two temperature extremes, burning tissue in RFA and 
freezing tissue in cryoablation, small tumors in a number of important anatomical locations can 
be effectively destroyed.  In terms of local treatment strategies, cryo-ablation is an attractive 
treatment modality for the following reasons:   1) It has been shown to be safe and effective in 
treating kidney, liver, bone, lung, adrenal and soft tissue masses; 2) It is palliative with the 
freezing procedure causing a local analgesic effect; 3) It has been shown to be potentially cost-
effective in oligometastatic disease 1.  Cryosurgery has been interesting to immunologists and 
oncologists for decades due to a rare Abscopal type of effect witnessed in several case reported 
prostate and breast cancer patients 2 3.   Cryo-ablation induces membrane disruption, solution 
effects, organelle disruption, ice crystallization, and microvascular thrombosis 4.  Depending on 
the proximity to the cryo-probe, cells appear to be influenced by the different insults in varying 
degrees.  In sum, certain cells appear to experience a necrotic cell death, while others undergo 
apoptosis.  The mechanism of cell death appears to be important in optimally stimulating an 
immune response.  In an in vitro system evaluating the maturation of immature dendritic cells, 
adding living fibroblasts and apoptotic fibroblasts yielded no maturation, while adding necrotic 
fibroblasts resulted in significant maturation 5.  Using bone marrow-derived murine macrophages 
stimulated by either tumor cells undergoing UV induced apoptosis or cryotherapy induced 
necrosis, Reiter et al found macrophages exposed to necrotic cells exhibited significant antitumor 
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effect while those exposed to apoptotic cells were immunosuppressed 6.  Work by Sauter et al. 
found immature dendritic cells (DCs) are capable of phagocytosis of both apoptotic and necrotic 
tumors cells allowing for cross presentation to CD8+ T cells. Only necrotic tumor cells and a 
supernatant generated from necrotic tumor cells were capable of maturing DCs allowing for 
activation of resting CD4+ and CD8+ T cells thus mounting a specific anti-tumor response.  
Apoptotic cells and a supernatant generated from apoptotic cells were not capable of inducing 
this maturation  7.   
Whether the creation of therapeutic apoptosis or necrosis in tumor cells is 
immunosuppressive or immune-stimulatory has led to much debate.  The danger theory proposed 
by Polly Matzinger broke from the traditional model that the immune system’s main role is to 
recognize self vs non-self.  In her model, Matzinger proposed the immune system is designed to 
recognize cell injury as danger and to react to these insults 8.   Necrosis leads to the denaturing of 
proteins and break down of the cell wall integrity leading to the release of important 
inflammatory molecules including High mobility group 1 (HMGB1), uric acid, and heat shock 
proteins (HSP) including hsp70, hsp90, calreticulin, and gp96 9,10 11.  Scaffidi et al, found that 
HMGB1 was important for inducing inflammation and enhanced DC maturation, while apoptosis 
primary or secondary did not release HMGB1 10.  Basu et al. found the release of HSP induced 
macrophages to secrete cytokines and induced maturation of DC interacting through the NF-κB 
9.  Shi et al. identified uric acid as an important molecule in dendritic cell maturation 11.  Scheffer 
et al. tested apoptotic and necrotic tumor cells injected into a murine model followed by live 
tumor cell injection and found apoptotic cells induced significant protection and prolonged 
survival, while necrotic cell vaccine provided little protection 12.   Conversely, Kotera et al. 
found pulsing dendritic cells with apoptotic cells produced by ultraviolet B exposure or necrotic 
3 
 
cells produced via freeze/thaw cycles produced equivalent dendritic cell activation and similar 
anti-tumor effect 13.  Gamrekelashvili et al. used ganciclovir to induced tumor cell apoptosis and 
a vascular targeting drug, ZD6126, to procedure necrotic tumor cells.  In these experiments, the 
group found when transferring lymphocytes from the spleen and tumor draining lymph nodes to 
other tumor bearing mice, mice receiving cells from the ganciclovir treated mice were afforded 
protection while no protection was provided to the mice receiving cells from mice treated with 
ZD6126.  The authors showed this protection was conferred by the CD8+ T cells 14.   Feng et al. 
found a significant difference in the immunostimulatory nature of non-stressed and heat-stressed 
apoptotic leukemic cells, with heat-stressed cells capable of inducing maturation of dendritic 
cells 15.  As a result of these studies, the context and rapidity of induction of necrotic and 
apoptotic cells appears to be important in the generation of an immune-reactive or 
immunosuppressive response.   
Kolicher is credited by Strauss as introducing electrocoagulation (surgical diathermy) to 
inoperable cancer in 1910 16.  In the same publication, Strauss reported his experience treating 
rectal carcinoma with surgical diathermy he wrote:   
“Clinically the results are remarkable.  After the first or second application of diathermy 
the patient gains weight and the hemoglobin and red cell content and red cell count of the 
blood are increased to normal levels.  Even a patient who has lost a great deal of weight 
or is cachectic loses all the appearances that are characteristic of a person with advanced 
carcinoma.”16   
 
In this work, Strauss hypothesized the reticulo-endothelial system was involved in the dramatic 
responses seen in patients treated with this approach.  Using pigs, McGahan et al. studied the 
local effects of radiofrequency ablation (RFA) via ultrasound and under both gross and 
microscopic dissection at autopsy 17.  At the site of the RFA probe a central char was observed. 
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This char was surrounded by an area of cells that undergo necrosis, the third outer area contained 
areas of hemorrhage and congestion.  The injury evolved over the period of weeks with 
eventually the area being walled off with granulation tissue and chronic inflammatory cells 
leading to scar.     
Using a VX2 hepatoma model in rabbits, Wissniowski et al. found animals treated with 
RFA compared to observation had a significant infiltration of T cells within the tumors and 
evidence of persistent specific circulating T cells 18.   den Brok et al. using a murine model 
injecting B16-OVA melanoma cells into the flank that RFA alone protected 20% of animals 
repeated B16-OVA cellular rechallenge in the contralateral flank, but did not protect against 
challenge with a thymoma cell line.   This protection was transferrable to other animals when 
splenocytes were transferred and was significantly reduced when plasma was used, indicating 
that the cellular portion of the immune arm provided the effect.  Also, RFA combined with 
CTLA4 blockade was more effective than RFA alone in protecting animals against tumor 
rechallenge and greatly enhanced survival 19.   Radiofrequency ablation in a murine urothelial 
carcinoma model generated systemic T cell responses with increased infiltration of dendritic 
cells within the tumors 20.   
In humans, RFA in metastatic liver tumors compared to RFA in localized hepatocellular 
carcinoma (HCC) tumors produced evidence of trafficking T cells from the systemic circulation 
to the tumor site with a period of decreased T cells in the peripheral circulation.  The T cells in 
the tumors were found have a strong proliferative response and produced the Th1-associated 
cytokine, IFN-γ, to tumor associated antigen MUC1  21.  In an additional study of 12 patients, 6 
with HCC, 6 with metastatic colorectal cancer to the liver, RFA to the liver lesion produced T 
cells in the peripheral circulation that were specific and produced IFN-γ were significantly 
5 
 
elevated at both 4 and 8 week time points after the procedure 22.  In a study of 20 patients with 
localized HCC unfit for liver transplantation or surgical resection, RFA produced increased 
frequency of circulating IFN-γ producing specific T cells.  However, despite the presence of 
these cells, patients were not protected against relapse from HCC 23.   Zerbini’s group later 
showed in a group of 20 patients the necrotic tissue collected immediately following RFA for 
HCC are capable of inducing maturation of antigen presenting cells (APCs) capable of producing 
specific T cells for HCC  24.   
Animal modeling has found cryosurgery under certain conditions to be 
immunostimulatory and others immunosuppressive 4,25.   Both Sabel and Sidana reviewed the 
animal modeling systems that have explored cryoimmunology and provide summaries of these 
experiments.   The initial studies evaluating the immune response to cryoablation involved using 
a rabbit model subjected to cryoablation of the male sex organs resulting in a the production of 
tissue specific auto-antibody response26,27.  Myers et al. used multiple mouse types with both 
fibrosarcoma and mammary cell tumor types and found cryosurgery was more protective against 
rechallenge with the same tumor type than to amputation or control, but was unable to protect 
against rechallenge with a different tumor type 28.  Using a rat model, Blackwood et al. found 
that animals who received cryoablation of both myosarcoma and carcinosarcoma cell line- 
derived tumors were protected against tumor rechallenge and intraperitoneal implantation 29.  
Neel et al. compared mice with virally induced mammary adenocarcinoma or chemically 
induced sarcoma treated with surgery, cryoablation, or ligation and found mice treated with 
cryoablation had longer time until tumor recurrence and improved survival after tumor 
rechallenge 30.  Bagley et al. compared mice with chemically induced limb sarcoma treated with 
cryosurgery, observation, amputation and harvested splenic lymphocytes.  The splenic 
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lymphocytes from the cryosurgically treated animals had specific cytotoxicity against the 
chemically induced sarcoma cell lines, but less so against other cancer cell lines 31.  In a rat 
model using metastasizing rat's mammary tumor (MRMT-1), cryosurgery was compared to 
surgical excision and using the Winn neutralization assay was found to initially be less 
immunosuppressive than surgery alone.  Based on these findings, the authors concluded the 
underlying immunosuppressive nature of cryosurgery was related to the development of a 
suppressor cell response 32.    Using the same rate model, Misio et al. found animals treated with 
cryosurgery had evidence of tumor regression and protection against the development of lung 
and lymph node metastasis, which peaked at 10 weeks following the procedure.  In contrast, 
animals treated with surgical excision had continued progressive risk of developing lung and 
lymph node metastasis that increased with time 33.   
In a study of 20 patients with high risk localized prostate cancer treated with 
cryoablation, patients’ serum cytokine levels and immune cyto-lytic activity was assessed at 
baseline, after 4 weeks and after 8 weeks 34.  The serum cytokines of interest included classic 
Th1 cytokines interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) and classic 
Th2 cytokines interleukin 4 (IL-4) and interleukin 10 (IL-10) with the authors evaluating the 
Th1/Th2 ratio of IFN-γ/IL-4.  The authors found the Th1/Th2 ratio was increased at 4 weeks, but 
diminished at 8 weeks, suggesting the response was favorable, but not sustained.   The T cells 
were also found to be cyto-lytic to a prostate cell line and not to a renal cell carcinoma cell line 
supporting specificity of response.    
In renal cell carcinoma (RCC), the ratio of Th1 to Th2 cytokines produced by T cells has 
been found to inversely correlate with tumor grade and stage 35.  Murine modeling has found 
diminished Th1 cytokine production and responsible T cell subset presence during tumor 
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progression 36. Alternatively, tipping the balance to more Th1 cytokine production as compared 
to Th2 can lead to tumor regression 37. 
In an in vivo melanoma mouse model, the authors sought to further understand 
mechanisms of influencing the immune system in animals treated with cryosurgery, 
radiofrequency ablation and tumor vaccination.  Both RFA and cryosurgery appeared to produce 
an in situ depot of tumor antigen and debris.  The authors used an indium labeled tracer, which 
was injected into the tumor.  Animals were then treated with a dendritic cell vaccine, 
radiofrequency ablation, cryoablation, or surgical resection.  The authors found within tumor 
draining lymph nodes of animals treated with cryosurgery an increase in immature dendritic cells 
which took up tumor antigen as well as mature dendritic cells.  The cryosurgery group was more 
resistant to tumor rechallenge and had the longest survival compared to all other animal groups 
included on study.  The authors also found the addition of anti-CTLA4 to cryosurgery or 
radiofrequency ablation resulted in a significant survival advantage after tumor re-challenge 
compared to animals treated with anti-CTLA4 alone, RFA alone, or cryosurgery 19. 
Within our current group at MD Anderson Cancer Center, work published by Dr. Matin 
showed the immunogenicity of cryosurgery in an orthotopic renal cell carcinoma mouse model.  
In this model, cryosurgery of a renal cell carcinoma harboring kidney led to significant 
infiltration of inflammatory cells including neutrophils, macrophages, and T cells compared to 
kidneys harboring renal cell carcinoma.18   Dr. Allison and his previous group at Memorial Sloan 
Kettering investigated pairing cryosurgery with ipilimumab in a TRAMP prostate cancer mouse 
model.  In this model, mice received a thigh injection with TRAMP C2 cells, one month before 
undergoing cryo-surgery or a sham procedure on the resulting mass.  The mice were then 
rechallenged the following day with an additional TRAMP C2 cell injection in the opposite 
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thigh.  The mice were then either treated with ipilimumab or placebo.  Finally a subset of mice 
received an anti-CD8 T cell antibody prior to cryosurgery and then at specific intervals during 
the study. The mice treated with the combination of cryosurgery and ipilimumab had a 
synergistic response with a significant delay in tumor re-growth and the longest overall survival 
within the study groups.  T cells found in mice from the cryosurgery plus ipilimumab group were 
specific against the TRAMP C2 cells.   These T cells were also active with high levels of IFN-
gamma detected in both the secondary tumors and spleens of the mice studied.  In contrast, mice 
treated with cryosurgery alone, ipilimumab alone, or cryosurgery combined with ipilimumab and 
anti-CD8 T cell antibody had a shortened time until tumor recurrence and a shorter survival 
compared to the ipilimumab plus cryosurgery group.  The authors concluded cryosurgery and 
CTLA-4 blockade in the TRAMP prostate cancer mouse model produced increased ratio of 
effector CD8 T cells compared to T regulatory cells, and provided a synergistic response in mice 
with observed systemic, specific immunity.19 
Currently, two classes of immune check point inhibitors have achieved FDA approval.  
The anti-CTLA-4 targeting antibody, ipilimumab was the first drug to show significant survival 
advantage in patients with metastatic melanoma leading to its FDA approval in this setting 38 .  
The second class targeting the PD-1/PDL-1 interface, with antibodies developed and tested in 
clinical trials leading to FDA approval in advanced melanoma and metastatic squamous cell 
carcinoma of the lung, with active testing in many additional tumor subtypes 39 40 41 42 43 44.  All 
of these agents showed exciting activity with subsets of patients experiencing durable responses.   
In the setting of mRCC, fewer patients have been enrolled on studies involving the 
immune check point inhibitors compared patients with advanced melanoma.  In the smaller 
sample sizes, both the agents targeting CTLA-4 and PD1/PDL-1 appear of similar to reduced 
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efficacy in mRCC as found in melanoma.  Granted, phase I trials assess safety and dose as the 
primary endpoints, but in each trial efficacy was a secondary endpoint. In the phase I trial 
evaluating ipilimumab, there was a response rate of 9.8%(6 of 61 pts) for all patients treated, 
though this increased to 12.5% (5 of 40pts) in the subset treated with maximum dosing 10mg/kg 
45.  In the phase I anti-PD-1 study, patients with mRCC had a 27% response rate (9 of 33pts) 42.  
Finally, in the anti-PD-L1 study, patients with mRCC had a response rate of 11.7% (2 of 17pts) 
46.   Our group has significant experience with the use of the immune check point inhibitors in 
clinical trials.  Dr. Sharma served as a co-led author on preoperative CTLA-4 blockade 47 48.   We 
currently have within the GU department a phase II trial evaluating ipilimumab plus androgen 
deprivation in prostate cancer, a phase I clinical trial evaluating nivolumab in combination with 
sunitinib, pazopanib, or ipilimumab in patients with mRCC, and are participating in the phase III 
trial PDL-1 vs. everolimus in patients with mRCC.   
 In the United States, in 2015, roughly 60,000 individuals will be diagnosed with a renal 
or renal pelvis neoplasm and 15,000 will die from these malignancies 49.  Renal cell carcinoma 
(RCC) represents the vast majority of these cases with the clear cell subtype being the most 
common histology accounting for 80% of RCC cases.  Surgical management for localized RCC 
remains the treatment of choice though 30% of patients with localized disease are destined to 
recur.  Metastatic RCC (mRCC) is considered largely incurable.  When patients with mRCC 
have long term disease free survival they typically have oligometastatic disease and are cured 
with aggressive surgery or when they have a complete response to an immunotherapy, which 
currently represents approximately 5%-10% of patients.    Immunotherapy was initially explored 
in mRCC in the form of cytokine therapy with high dose interleukin-2 (HD-IL-2) and interferon-
alpha (IFN-α) as all standard combination chemotherapy approaches and radiation treatments 
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were proven ineffective in the metastatic setting 50 51 52.  With HD-IL-2, 5-7% of patients with 
mRCC will have a complete response and even with prolonged follow up for well over a decade 
without relapse. Complete responses are restricted to clear cell histology and are most common 
in patients who have had a previous nephrectomy (removal of primary tumor) and in patients 
with lung only metastasis.     
 Though 7 agents have received United States Food and Drug Administration approval for 
the treatment of metastatic renal cell carcinoma over the last decade, none of these agents (all 
targeting either the vascular endothelial growth factor axis or mammalian target of rapamycin 
pathway) offer cure.  Continuing to expand the pool of patients responsive to immunotherapy is 
paramount to increasing the potential cure fraction for patients with mRCC.  Cryoablation and 
radiofrequency ablation are procedures readily available across the clinical spectrum.  At MD 
Anderson Cancer Center, a clinical trial investigating the use of a monoclonal CTLA-4 targeting 
antibody, tremelimumab, with or without cryoablation is planned.  In an effort to study the 
impact of cryoablation alone we sought to perform both retrospective and prospective analysis of 
patients who received thermal ablation at UT MD Anderson Cancer Center.   
 Based on this evidence, the central hypothesis of my project is thermal ablation 
procedures cause a significant local inflammatory response leading to an immunogenic gene 
signature that will be confirmed with detectable changes in immune cells identified in tissue and 
in the peripheral circulation.  In order to test this hypothesis the following aims were studied: 
1. To determine in a retrospective cohort of patients treated with thermal ablation followed 
by nephrectomy if an inflammatory, immunogenic signature is detected compared to 
patients treated with nephrectomy alone. 
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2. To determine in a retrospective cohort of patients if there is a correlation between the 
gene signature produced with thermal ablation followed by nephrectomy with changes 
detected in immunohistochemistry for specific immune cell subsets compared to patients 
treated with nephrectomy alone.    
3. To determine in a prospective cohort of patients if thermal ablation produces detectable 
changes in peripheral blood immune cell subsets and cytokine levels that can be detected 
over one day, four weeks, and a 6 month timeframe.    
II. Material and Methods 
 At UT MD Anderson Cancer 17 patients who underwent an ablative procedure from 
2004 to 2012 and later underwent a nephrectomy were retrospectively analyzed on protocol PA-
09-0383.  The nephrectomy samples were compared to 9 patients who received nephrectomy 
alone using immunohistochemical studies and gene microarray analysis.  On a separate arm of 
PA-09-0383, 13 patients who underwent an ablative procedure to the kidney were prospectively 
analyzed using blood based studies.       
Immunohistochemistry 
After nephrectomy, the specimen was formalin fixed and paraffin embedded.  
Appropriate blocks of tissue were selected by Dr. Priya Rao of the genitourinary pathology 
department.  Dr. Jorge Blando of the immunotherapy platform sliced the tissue into 5 μm 
sections.  Immunohistochemistry stains for CD3, CD4, CD8, CD20, CD45RO, CD57, CD68, 
FoxP3, Granzyme B, PD-1, and PD-L1 were performed as per protocol on the immunotherapy 
platform at UT MD Anderson Cancer Center.  The selection of these antibodies allowed for 
enumeration of specific T cell subsets CD3, CD4, CD8, CD45RO, regulatory T cell subset 
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FoxP3, cytotoxic cells Granzyme B, and the immune checkpoint axis PD-1 and PD-L1.  CD3, 
CD4, CD8, CD20, CD45RO, CD57, CD68, FoxP3, Granzyme B are validated antibodies.  PD-1 
and PD-L1 staining was confirmed by two pathologists Dr. Jorge Blando and Dr. Ignacio 
Wastuba.  If a discrepancy in scoring of staining existed, both pathologists reviewed the slides 
together to come to consensus.  Briefly, sections of 5 μm thickness were selected placed on 
charged slides heated overnight and then were deparaffinized using xylene and graded alcohols.  
Slides were then placed in a DAKO HipH buffer solution and heated to 97°C for 15 minutes.   
The slides were then incubated overnight with the primary antibody at 5°C.  The following 
morning the Powervision kit (Vision Biosystems) was used as the secondary antibody.  Exposure 
to diaminobenzidene served as the chromogene and counterstaining was performed using 
hematoxylin.  All tissue specimens were then evaluated using hematoxylin-eosin (H&E) 
staining.  A Leica system using Aperio software was used to tabulate the total number of stained 
cells/mm3 per 5 high power fields (HPF) at 20x magnification.  The PD-L1 h-score was 
calculated by taking the PDL-1 epithelial stained cells/PDL-1 tumoral stained cells.  Control 
patients received nephrectomy alone, ablation or treatment refer to patients who received an 
ablation procedure followed later by nephrectomy.  Distant refers to patients who underwent a 
non-renal ablation followed later by nephrectomy; local refers to patients who received ablation 
to the kidney followed by nephrectomy, which was either partial or radical. 
Peripheral Blood Collection and Processing 
 Blood was collected as per Dr. Padmanee Sharma’s laboratory protocol.   Blood was 
drawn into BD Venous Blood collection heparinized green top tubes.  Tubes were spun down at 
400 times gravity for 20 seconds and placed into polypropylene conicals.  The conicals were then 
spun at 410 times gravity for 10 minutes.  The plasma layer was then collected and spun at 885 
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times gravity for 10 minutes.  Aliquots of plasma were collected and placed into cryogenic vails 
and NUNC tubes.  Plasma was then diluted in a 1:1 ratio with Roswell Park Memorial Institute 
(RPMI) medium (Cellgro).  Ficolling blood was performed using Leucosep tubes.  In brief 15mL 
of lymphocyte separation medium (LSM) (Cellgro) was added to the Leucosept tube and 
centrifuged for 1 minute at 400 times gravity.  After centrifuging was completed, 35mL of 
plasma was added to Leucosept tube and centrifuged at 1000 times gravity for 12 minutes.  The 
plasma layer was then removed to the level of 1cm above the lymphocyte layer.  The lymphocyte 
layer was then collected into 50mL polypropylene conical tube.  The volume was then brought to 
50mL with RPMI medium.  The tube was then spun at 400 times gravity for 15 minutes.  The 
supernatant was decanted and the pellet was gently resuspended.  To remove any residual red 
blood cells, 30mL of ammonium chloride lysis buffer was added to the resuspended pellet.  The 
tube was then spun at 450 times gravity for 6 minutes.  The pellet was then harvested.  All 
resuspended pellets were combined into a 50mL polypropylene conical tube and brought to 
50mL volume with RPMI.  A 20μL aliquot was collected in a 12 x 75mm test tube and added to 
20 μL of 0.4% Trypan Blue (BioWhittaker).  The cell suspension concentration was determined 
with a hemacytometer.  Peripheral blood mononuclear cells (PBMCs) were isolated from plasma.   
Flow Cytommetry 
The following antibodies were used for flow cytommetry CD3 FITC, CD4 AmCyan, CD8 APC, 
CD19 FITC,  (BD PharMingen), CD45RO Pacific blue (Biolegend) ICOS PECy7 (eBioscience), 
FoxP3 PE (eBioscience), CD25 APC (EBioscience), LAP APC (R&D FAB), CD127 eflour 450 
(eBioscience), CD33 eflour 450 (eBioscience), CD14 PECy7 (eBioscience), CD16 APCCy (BD 
PharMingen, CD56 Pacific blue (Biolegend), CD11b APC (EBioscience).  Intracellular staining 
for FoxP3 was performed using manufacturer guidelines.  The antibodies were selected to 
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enumerate the presence of T cells, T cell subsets including potential regulatory and effector 
subsets, macrophage, myeloid derived suppressor cells, and dendritic cells.  Samples were 
analyzed using the FACSCanto II (Becton Dickinson) and data were then analyzed using BD 
FACSDiva software.    Gates were selected based on isotype controls as previously published 53 
54 47.  All samples were tested in triplicate.   
Cytokine Analysis 
 Patient plasma was used to perform cytokine analysis using the Meso scale discovery 
Th1/Th2 kit. 55  Samples were prepared and tested in triplicate as per manufacturer’s guidelines.  
Cytokines tested included interferon gamma (IFN-γ), interleukin-2 (IL-2), interleukin-4 (IL-4), 
interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12p70 (IL-12p70), 
interleukin-13 (IL-13), tumor necrosis factor alpha (TNF-α).  These cytokines were selected to 
quantify a variety of known Th1 and Th2 related cytokines.  Appropriate standards were used. 
The kits were analyzed on MDS QuickPlex SQ 120 per manufacturer’s guidelines.  All samples 
were tested in triplicate.    
Gene Microarray Analysis 
Total RNA was extracted from renal cell carcinoma (RCC) tissue using miRNeasy Kit (Qiagen). 
The gene expression was assessed by Affymetrix’s GeneChip Human 2.0 ST Array. Data was 
analyzed using the Ingenuity Platform Analysis as previously described 56.  
Statistical Analysis 
 Data were collected with Microsoft Excel.  All analysis was conducted using GraphPad 
Prism version 6 and SAS 9.4 software.  Due to the small sample sizes, non-parametric analysis 
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was conducted.  For immunohistochemistry, the student’s t test, Kruskal Wallis, and Dunn’s 
multiple comparison’s test were used to analyze the data.  The gene microarray analysis was 
conducted using the Ingenuity pathway analysis.  When comparing the normal renal tissue to 
renal cell carcinoma tissue, a fold cutoff of ±2 and p value cut off of 0.05 was employed 
allowing for a false positive call rate of 25%.  When comparing nephrectomy only to patients 
who underwent ablation prior to nephrectomy, a fold cutoff of ±1.5 and p value cut off of 0.05 
was used again allowing for a false positive call rate of 25%.  The beta-uniform mixture model 
(BUM model) was used to generate a histogram of the p values generated for the differentially 
expressed genes assuming a normal distribution.  For the flow cytommetry analysis and cytokine 
analysis the Friedman test was used to test for differences among groups when samples were 
matched over various time points, the Kruskal Wallis was used when samples were not matched 
to determine significant between groups, and the Dunn’s multiple comparisons test was used 
between to test for differences between multiple groups.  A one sided p value of 0.05 was used to 
reject the null hypothesis.    
III. Results 
Clinical Characteristics 
 Clinical characteristics for patients on the retrospective portion of the study are shown in 
Table 1.  Clinical characteristics for patients on the prospective portion of the study are shown in 
Table 2.   
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 Nephrectomy 
Only 
N=9 
Radiofrequency 
Ablation 
N = 11 
Cryoablation 
N = 6 
Age (years) 67±11.9 64±10.8 years 66±7.3 years 
Race 
     Caucasian 
     Black 
     Hispanic      
 
4 (44%) 
2 (22%) 
3 (33%) 
 
9 (82%) 
1 (9%) 
1 (9%) 
 
4 (67%) 
0 
2 (33%) 
Histology 
Clear Cell 
Other 
 
8 (89%) 
1 (11%) 
 
9 (82%) 
2 (18%) 
 
6 (100%) 
0 
Clinical T Stage 
T1a 
T1b 
≥T2 
Unknown 
 
Pathologic T Stage 
T1a 
T1b 
T2 
T3a 
 
Metastatic Disease 
No  
Yes 
 
6 (67%) 
3 (33%) 
0 
0 
 
 
6 (67%) 
3 (33%) 
0 
0 
 
 
9 (100%) 
 
7 (64%) 
2 (18%) 
0 
2 (18%) 
 
 
8 (73%) 
2 (18%) 
0 
1 (9%) 
 
 
8 (73%) 
3 (27%) 
 
3 (50%) 
3 (50%) 
0 
0 
 
 
2 (33%) 
3 (50%) 
0 
1 (17%) 
 
 
3 (50%) 
3 (50%) 
Time (Ablation to 
Surgery) years 
       <     1 year 
 1 year 
 
 
 
1.6 ± 1.6 
4 (36%) 
7 (64%) 
 
0.9 ± 1.6 
4 (66%) 
2 (33%) 
 
 
 
 
Table 1 Clinical Characteristics of Retrospective Patients: Nephrectomy Only (control), 
radiofrequency ablation followed by nephrectomy, and cryoablation followed by nephrectomy  
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 Radiofrequency Ablation 
N = 8 
Cryoablation 
N = 5 
Age (years) 64 ± 13 71 ±12.8 
Race 
    White 
    Hispanic 
 
7 (87%) 
1 (13%) 
 
3 (60%) 
2 (40%) 
Histology 
    Clear cell 
    Other  
 
6 (75%) 
2 (25%) 
 
5 (100%) 
0% 
Clinical Stage 
  T1a 
 
8 (100%) 
 
5 (100%) 
Von Hippel Lindau 
       Yes 
       No 
 
1 (13%) 
7 (87%) 
 
1 (20%) 
4 (80%) 
 
 
 
 
 
 
 
 
 
 
Table 2 Clinical Characteristics: Prospective patients treated with ablation followed by serial 
blood draws. 
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Gene Microarray Analysis 
 The gene microarray analysis was performed through the Ingenuity Pathway Analysis 
(IPA).  The initial unbiased analysis of both tumor tissue versus normal tissue and ablated tissue 
vs. control tissue was carried out using 10 tumor samples and 8 normal kidney specimens.  A 
total of 719 genes were found to be differentially expressed between the normal and tumor 
tissue.  Using a fold cutoff of ±2 and p value cut off of 0.05 allowing for a false positive call rate 
of 25%, 195 genes were found to have a significant positive change in expression and 524 were 
found to have a negative change in expression.   Table 3 shows the 20 most up-regulated 
pathways involved, Table 4 shows the 10 most positive differentially expressed genes and table 5 
shows the 10 most negative differentially expressed genes.   Ingenuity groupings of genes 
includes location, pathways involved, processed involved, diseases involved, and interaction.  
For example a pathway normally involves signaling, processes involve transport/activation, and 
interaction involves the number of other genes an individual gene influences or is influenced by 
according to Ingenuity.   
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Pathways DEGs pValue 
LPS/IL-1 Mediated Inhibition of RXR Function 23 4.70868E-06 
Glycine Betaine Degradation 5 1.25694E-05 
Complement System 7 0.00013831 
α-tocopherol Degradation 3 0.000177904 
Coagulation System 7 0.000204598 
Xenobiotic Metabolism Signaling 23 0.000280209 
4-hydroxyproline Degradation I 2 0.0012802 
β-alanine Degradation I 2 0.0012802 
Sucrose Degradation V (Mammalian) 3 0.002235949 
PXR/RXR Activation 8 0.002620771 
Valine Degradation I 4 0.003336923 
FXR/RXR Activation 9 0.003611253 
Methionine Salvage II (Mammalian) 2 0.003749206 
Atherosclerosis Signaling 11 0.004123248 
LXR/RXR Activation 11 0.004123248 
Retinoate Biosynthesis I 5 0.005232584 
Uracil Degradation II (Reductive) 2 0.007320507 
Arginine Degradation I (Arginase Pathway) 2 0.007320507 
Thymine Degradation 2 0.007320507 
D-glucuronate Degradation I 2 0.007320507 
 
Table 3: Tumor Tissue versus Normal Tissue Top 20 Pathways Upregulated  
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Symbol: Name Fold Change Notes Molecular 
Function 
Location Pathways Processes Diseases Interactions 
TNFAIP6: tumor necrosis 
factor, alpha-induced 
protein 6 
10.59 0 Other Extracellular 
Space 
1 6 4 2  
C3: complement 
component 3 
9.325 1 Peptidase Extracellular 
Space 
5 114 41 13  
LOX: lysyl oxidase 5.61 1 Enzyme Extracellular 
Space 
1 23 14 4  
LAMA4: laminin, alpha 4 4.639 1 Enzyme Extracellular 
Space 
0 13 18 0  
FABP4: fatty acid binding 
protein 4, adipocyte 
4.639 1 Transporter Cytoplasm 1 51 17 5  
NNMT: nicotinamide N-
methyltransferase 
4.513 1 Enzyme Cytoplasm 0 1 12 1  
ST8SIA4: ST8 alpha-N-
acetyl-neuraminide alpha-
2,8-sialyltransferase 4 
4.504 0 Enzyme Cytoplasm 0 18 0 2  
HILPDA: hypoxia inducible 
lipid droplet-associated 
4.466 1 Other Cytoplasm 0 1 7 1  
DNAH11: dynein, 
axonemal, heavy chain 11 
4.048 1 Enzyme Cytoplasm 0 2 14 0  
EBF2: early B-cell factor 2 4.036 1 Other Nucleus 0 13 10 0  
 
 
 
 
 
 
 
 
 
Table 4: 10 Most up-regulated genes comparing renal cell carcinoma tissue to normal tissue 
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Symbol: Name Fold 
Change 
Notes Molecular 
Function 
Location Pathways Processes Diseases Interactions 
EGF: epidermal growth factor -13.691 1 growth 
factor 
Extracellular 
Space 
30 120 19 31 
MT1H: metallothionein 1H -16.098 1 Other Unknown 0 36 20 4 
ALDOB: aldolase B, fructose-
bisphosphate 
-16.969 1 Enzyme Cytoplasm 4 2 8 5 
SCNN1G: sodium channel, non-
voltage-gated 1, gamma 
subunit 
-20.544 0 ion channel Plasma 
Membrane 
2 25 9 6 
MUC15: mucin 15, cell surface 
associated 
-21.564 0 Other Extracellular 
Space 
0 0 0 0 
MT1G: metallothionein 1G -22.472 1 Other Unknown 0 0 9 1 
KNG1: kininogen 1 -37.356 1 Other Extracellular 
Space 
8 85 18 13 
UMOD: uromodulin -46.644 1 Other Extracellular 
Space 
0 33 25 3 
AQP2: aquaporin 2 (collecting 
duct) 
-48.554 0 Transporter Plasma 
Membrane 
1 9 8 5 
SLC12A1: solute carrier family 
12 (sodium/potassium/chloride 
transporters), member 1 
-74.282 1 Transporter Plasma 
Membrane 
1 33 28 3 
 
 
 
 
 
 
 
 
 
 
Table 5:  10 most down regulated genes comparing renal cell carcinoma tissue to normal tissue 
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For Ingenuity pathway analysis for ablation versus nephrectomy only, a fold change cut 
off of ±1.5 p≤0.05 was used to detect differentially expressed genes with again a false positive 
call rate of 25%.  A total of 10 nephrectomy alone patients and 5 nephrectomy following ablation 
patients were used for this analysis.   A total of 495 differentially expressed genes were 
identified in this analysis.  Table 6 shows the top 20 pathways altered by ablation as compared to 
nephrectomy alone.  The Table shows the number of differentially expressed genes and the 
cumulative significance of the pathway.  Of note, 9 pathways are directly involved in immune 
cell quantity, movement, connectivity, and function.  Of particular interest is the connection 
between innate and adaptive immunity and dendritic cell maturation.  Table 7 shows the top 30 
biologic processes and is represented in similar fashion as table 6.  Every biologic process 
represented is involved in immune response.  Table 8 and Table 9 detail the top 20 up-regulated 
and top 20 down-regulated genes respectively.  Both tables are designed in the same format as 
Table 5 discussed above. Whether the differences in groups reflects biologic differences, 
differences in immune cell infiltrate, or differences in the tumor stroma are not known or 
characterized in our analysis.    
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Pathways DEGs pValue 
Atherosclerosis Signaling 15 2.05E-07 
Granulocyte Adhesion and Diapedesis 17 9.32E-07 
PI3K Signaling in B Lymphocytes 14 2.41E-06 
Inhibition of Matrix Metalloproteases 8 3.26E-06 
Leukocyte Extravasation Signaling 17 5.95E-06 
Phospholipases 9 7.77E-06 
Eicosanoid Signaling 8 0.000111 
Dendritic Cell Maturation 13 0.00037 
Caveolar-mediated Endocytosis Signaling 8 0.000385 
Agranulocyte Adhesion and Diapedesis 13 0.000508 
Airway Pathology in Chronic Obstructive Pulmonary Disease 3 0.0007 
Axonal Guidance Signaling 22 0.000713 
Gαq Signaling 11 0.00089 
Prostanoid Biosynthesis 3 0.001031 
Crosstalk between Dendritic Cells and Natural Killer Cells 8 0.001422 
Communication between Innate and Adaptive Immune Cells 8 0.001527 
Endothelin-1 Signaling 11 0.002822 
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid 
Arthritis 
16 0.002935 
D-myo-inositol (1,4,5)-Trisphosphate Biosynthesis 4 0.003688 
Phospholipase C Signaling 13 0.004362 
 
 
 
 
 
 
 
 
 
Table 6: Top 20 Pathways Altered by Ablation versus surgery alone 
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Biological Process DEGs pValue 
cell movement of leukocytes 75 9.88421E-22 
leukocyte migration 80 6.26341E-21 
cell movement of myeloid cells 57 4.45404E-19 
quantity of leukocytes 78 5.18822E-18 
cell movement of granulocytes 44 3.89424E-17 
proliferation of lymphocytes 65 1.18815E-16 
cell movement 123 1.28232E-16 
proliferation of blood cells 71 1.47787E-16 
proliferation of immune cells 68 2.20192E-16 
infiltration of cells 44 6.12338E-16 
cell movement of phagocytes 53 8.08087E-16 
infiltration of leukocytes 42 1.58868E-15 
shape change of leukocytes 20 1.79493E-15 
cell death of immune cells 59 3.57496E-15 
migration of cells 111 3.99319E-15 
function of leukocytes 53 4.44619E-15 
cell movement of neutrophils 36 4.60373E-15 
cell death of blood cells 60 6.8719E-15 
inflammatory response 60 2.37932E-14 
cell movement of mononuclear leukocytes 46 2.80598E-14 
activation of leukocytes 57 3.1411E-14 
antibody response 26 3.48625E-14 
migration of mononuclear leukocytes 39 6.75305E-14 
Necrosis 136 1.34569E-13 
binding of cells 47 1.36191E-13 
quantity of lymphocytes 59 1.54307E-13 
cell movement of lymphocytes 40 1.91728E-13 
activation of cells 71 3.29801E-13 
quantity of T lymphocytes 49 3.55297E-13 
proliferation of T lymphocytes 52 4.71932E-13 
 
 
Table 7:  Top 30 biologic processes altered by ablation compared to surgery alone 
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Symbol: Name Fold 
Change 
Notes Molecular 
Function 
Location Pathways Processes Diseases Interactions 
SLC12A1: solute carrier 
family 12 
(sodium/potassium/chloride 
transporters), member 1 
12.311 1 Transporter Plasma 
Membrane 
1 5 10 1 
MMP12: matrix 
metallopeptidase 12 
(macrophage elastase) 
9.899 1 Peptidase Extracellular 
Space 
7 43 22 4 
KIAA1199: KIAA1199 8.481 1 Other Cytoplasm 0 0 10 0 
ALDOB: aldolase B, fructose-
bisphosphate 
8.273 1 Enzyme Cytoplasm 4 0 6 3 
UMOD: uromodulin 7.863 1 Other Extracellular 
Space 
0 21 13 0 
DPT: dermatopontin 6.98 1 Other Extracellular 
Space 
0 3 9 1 
IBSP: integrin-binding 
sialoprotein 
6.282 1 Other Extracellular 
Space 
0 6 12 3 
MT1G: metallothionein 1G 6.104 1 Other Unknown 0 0 12 1 
MMP9: matrix 
metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
5.225 1 Peptidase Extracellular 
Space 
21 113 48 34 
LRRC15: leucine rich repeat 
containing 15 
5.201 1 Other Plasma 
Membrane 
0 1 9 1 
COMP: cartilage oligomeric 
matrix protein 
5.073 0 Other Extracellular 
Space 
0 8 3 0 
KNG1: kininogen 1 4.931 1 Other Extracellular 
Space 
8 72 19 7 
AQP2: aquaporin 2 
(collecting duct) 
4.591 0 Transporter Plasma 
Membrane 
1 2 1 2 
CCL19: chemokine (C-C 
motif) ligand 19 
4.338 1 Cytokine Extracellular 
Space 
2 127 10 3 
CHI3L1: chitinase 3-like 1 
(cartilage glycoprotein-39) 
3.988 1 Enzyme Extracellular 
Space 
1 50 21 4 
C7: complement component 
7 
3.847 1 Other Extracellular 
Space 
2 2 17 2 
MS4A1: membrane-
spanning 4-domains, 
subfamily A, member 1 
3.708 1 Other Plasma 
Membrane 
0 37 20 3 
LGI2: leucine-rich repeat LGI 
family, member 2 
3.524 1 Other Extracellular 
Space 
0 0 9 0 
PLA2G7: phospholipase A2, 
group VII (platelet-activating 
factor acetylhydrolase, 
plasma) 
3.511 1 Enzyme Extracellular 
Space 
8 30 7 0 
RANBP3L: RAN binding 
protein 3-like 
3.502 0 Other Unknown 0 0 0 0 
 
 
 
Table 8:  Top 20 most upregulated genes comparing ablation to surgery alone 
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Symbol: Name Fold 
Change 
Notes Molecular 
Function 
Location Pathways Processes Diseases Interaction
s 
PLA1A: phospholipase A1 
member A 
-2.259 0 Enzyme Extracellula
r Space 
1 1 0 2 
ARHGEF28: Rho guanine 
nucleotide exchange factor 
(GEF) 28 
-2.273 1 Other Cytoplasm 0 7 9 0 
HOXA4: homeobox A4 -2.382 1 transcriptio
n regulator 
Nucleus 0 8 15 0 
PDE11A: phosphodiesterase 
11A 
-2.472 1 Enzyme Cytoplasm 6 2 12 0 
PLA2G16: phospholipase A2, 
group XVI 
-2.488 0 Enzyme Nucleus 8 7 0 0 
VLDLR: very low density 
lipoprotein receptor 
-2.507 0 Transporter Plasma 
Membrane 
2 6 4 0 
EGFR: epidermal growth 
factor receptor 
-2.515 1 Kinase Plasma 
Membrane 
36 83 23 40 
ARHGEF35: Rho guanine 
nucleotide exchange factor 
(GEF) 35 
-2.64 0 Other Unknown 0 0 0 0 
KIF21A: kinesin family 
member 21A 
-2.718 1 Other Cytoplasm 0 0 11 0 
SPINK13: serine peptidase 
inhibitor, Kazal type 13 
(putative) 
-2.768 0 Other Unknown 0 0 0 0 
MT1L: metallothionein 1L 
(gene/pseudogene) 
-2.836 0 Other Cytoplasm 0 0 5 2 
SERPINI1: serpin peptidase 
inhibitor, clade I 
(neuroserpin), member 1 
-2.866 0 Other Extracellula
r Space 
0 4 6 1 
C19orf33: chromosome 19 
open reading frame 33 
-2.922 0 Other Nucleus 0 0 0 0 
 
 
 
 
 
 
 
Table 9:  Top 10 most downregulated genes comparing ablation to surgery alone 
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To help confirm quality control and to enhance our analysis we were assisted by the 
Bioinformatics Department at UT MD Anderson Cancer Center.   In this analysis, one sample in 
the post ablation group was found to be significantly different than the rest and was excluded 
from additional analysis.  The quality control analysis is shown in Table 10 and Figure 1 
revealing a significant outlier.  As a result, of the four post treatment samples remaining 3 were 
from patients who received radiofrequency ablation and 1 had received cryoablation prior to 
nephrectomy.  Using a beta-uniform mixture model or BUM model, the distribution of p values 
was tabulated and the generated histogram is found in Figure 2.  In this model, the assumption is 
there will be no significant interesting genes and the p-values should fall in a normal distribution 
curve.  If the p-values all segregate close to 0, this indicates a higher likelihood of detecting 
important findings 57.  Figure 3 displays the most significant core pathways altered.  In this table, 
the –log of the p value is represented on the Y axis, with higher bar graphs indicating greater 
likelihood of significance.  The color of the bar graph indicates the Z-score in relationship to 
standard value of the canonical signaling pathways.  If the bar is orange the pathway is 
significantly upregulated.   If the bar is white the pathway is similar to normal observed signaling 
levels.  If the bar is blue it is significantly down-regulated and if the bar is gray the baseline 
signaling characteristics are not well defined at this time.  Finally the ratio represented refers to 
the number of genes significantly up-regulated or down-regulated and is divided by the total 
number of genes in the pathway.  
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 Sample 1 Samples 2 Samples 3 Sample 4 Sample 5 
Sample 1 1 0.9 0.9 0.4 0.9 
Sample 2  0.9 1 0.9 0.4 0.9 
Sample 3 0.9 0.9 1 0.4 0.9 
        Sample 4  0.4 0.4 0.4 1 0.4 
Sample 5 0.9 0.9 0.9 0.4 1 
 
 
 
 
 
 
 
 
 
 
 
Table 10: Quality control (QC) assessment shows that one sample of the post treatment group 
appears to be an outlier and one of the samples in the pretreatment is distinct from other samples.  
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Figure 1: QC assessment shows that one sample of the post treatment group appears to be an 
outlier and one of the samples in the pretreatment is distinct from other samples.  
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Figure 2: Histogram of p values BUM model: 4 post treatment samples were compared with 9 
nephrectomy only samples. 
 
 
31 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Core pathways altered. IPA core pathway analysis. Settings: p value cutoff: 0.05; Log 
ratio cutoff 0.4. 
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 In an attempt to gain more uniformity, the Ingenuity pathway analysis was performed 
excluding the cryoablation sample and included the three samples treated with radiofrequency 
ablation prior to nephrectomy again using nephrectomy only as the comparator arm.  In this 
analysis, Figure 4 is the histogram from the BUM model and shows significant improvement as 
compared to the BUM model generated in Figure 2, with the majority of p values approaching 0.  
Figure 5 shows the core pathways altered and uses the same approach for analysis described 
above for Figure 3.  The top pathway was “Connection between Innate and Adaptive Immune 
Cells”.  The majority of the top pathways involve immune cell signaling, maturation, 
differentiation, trafficking, and inflammation.  Table 11 lists the top regulatory upstream 
molecules and their downstream targets.  All molecules included on this list except one (SND1), 
directly target immune signaling.        
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Figure 4: Histogram of p values: 3 post treatment samples were compared with 9 nephrectomy 
only samples. 
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Figure 5: Core pathways altered. IPA core pathway analysis. Settings: p value cutoff: 0.05; Log 
ratio cutoff 0.4.  The most significant pathway altered is “communication between innate and 
adaptive immune cells” pathway.  
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Table 11: Upstream pathway regulators; the columns are as follows: Gene name of the upstream 
regulator, log ratio of the upstream regulator in the dataset, activation z-score, and target 
molecules.  
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Immunohistochemistry (IHC) 
The tumoral and peritumoral infiltration of cytoplasmic staining CD4+ cells were 
tabulated for patients who underwent nephrectomy alone (control), patients who underwent any 
ablation procedure prior to nephrectomy (treatment), patients who underwent a distant ablation 
to a site other than the renal primary tumor (distant), and patients who underwent an ablation to 
the kidney and later had a nephrectomy (local).  Figure 6, Figure 7, and Figure 8 show examples 
of IHC staining for CD3, CD4, CD8, CD20, CD57, CD68, FoxP3, Granzyme B, PD-1, PD-L1 
tumoral cells, PD-L1 immune cells.  Slides were selected to involve normal renal tissue, the 
invasive margin, and tumoral tissue, Figures 6-8 represent examples of slides used in analysis.  
In Figure 6, CD3 is a pan marker for T cells capturing both CD4 and CD8 T cell populations.  
CD4 and CD8 are T cell subset markers and CD20 is a marker for B cell populations.  In Figure 
7, CD45RO stains for T cell memory subset, CD57 stains for NK cells, and CD68 for 
macrophages.  In Figure 8, FoxP3 is stained to capture a T cell regulatory subset of cells, 
Granzyme B stains cytotoxic cells, PD-1 stains immune cells expressing this immune check 
point, and PD-L1 stains both tumoral and immune cells expressing this immune check point 
ligand.   
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Figure 6: Immunohistochemistry staining: CD3 T cell marker, CD4 subset of T cells, CD8 
subset of T cells, CD20 marker of B cells. Each slide contained a section of normal renal 
architecture (N), the invasive margin (IM), and the center of tumor (CT).  Cells were stained and 
the number of stained cells/mm3 per 5 high power fields (HPF) at 20x magnification was 
quantified.   
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Figure 7: Immunohistochemistry staining: CD45RO a stain for a subset of T cell memory cells, 
CD57 a stain for natural killer (NK) cells, CD68 a stain for macrophages. Each slide contained a 
section of normal renal architecture (N), the invasive margin (IM), and the center of tumor (CT).  
Cells were stained and the number of stained cells/mm3 per 5 high power fields (HPF) at 20x 
magnification was quantified.   
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Figure 8: Immunohistochemistry: FoxP3 a stain for regulatory T cells, Granzyme B a stain for 
active cytotoxic T cells, PD-1 I(programmed death receptor 1), PD-L1 (programmed death 
receptor ligand 1).  Each slide contained a section of normal renal architecture (N), the invasive 
margin (IM), and the center of tumor (CT).  Cells were stained and the number of stained 
cells/mm3 per 5 high power fields (HPF) at 20x magnification was quantified.   
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Figures 9 through 14 represent the analysis of IHC that were initially performed by Dr. 
Priya Rao.  The IHC stains included CD4, CD8, CD45RO, Granzyme B, FoxP3, KP-1 (a stain 
for macrophages).  In Figures 9 through 14, the entire population of patients was analyzed in the 
top graph and only patients who received nephrectomy within 1 year (control and ablation 
patients) were evaluated in the bottom graph.  No significant differences were detected in CD4+ 
T cells (Figure 9), CD8+T cells (Figure 10), CD45RO+T cells (Figure 11), Forkhead P3 (FoxP3) 
(Figure 12) Granzyme B (Figure 13), or KP-1 (CD68) (Figure14) in the entire population or 
analyzing patients who received nephrectomy within 1 year following ablation.   
 In 2014, the methods of enumerating staining immune cells were changed to be 
consistent across all studies using the immunotherapy platform.  The changes included having 
each slide capture a section of normal renal architecture, the invasive margin, and the tumor.  In 
an effort to be consistent with future studies, we selected appropriate tumor blocks, recut tissue, 
and re-stained slides using the new immunotherapy platform selected stains.   Figures 15 thru 17 
represent the percent staining of cells in normal tissue (N) referring to renal tissue that is not 
intimately involved with tumor, the invasive margin (IM), and the center of tumor (CT).  Control 
refers to patients who were treated with nephrectomy alone and ablation refers to patients who 
received ablation.  We selected only patients who received nephrectomy within one year 
following an ablation procedure for this repeat analysis.  Unfortunately, 3 patients’ tissue blocks 
had significant fixation artifacts and were unable to be used.  We are attempting to locate at this 
time whether additional tissue blocks are available.  In Figure 15, no differences were detected 
by student’s T test when comparing CD3+T cells, CD4+ T cells, CD8+ T cells, and CD45RO+ T 
cells between patients treated with nephrectomy alone or ablation later followed by 
nephrectomy.  The portions of the slide labeled as N, IM, and CT, revealed no differences 
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between the two groups of patients.  In Figure 16, CD20+ B cells, CD68+ macrophages, FoxP3 
(regulatory T cell stain), and granzyme B (cytotoxic T cell stain) were analyzed and no 
detectable difference was found between groups.  In Figure 17, a difference between PD-1 
staining was found between the IM and a trend toward difference in the CT was detected, with 
more staining being detected in patients treated with ablation compared to nephrectomy alone.  
Other analysis in Figure 12 included the PD-L1 staining in tumoral and immune cells, and the 
PD-L1 H score did not find a significant difference between the two groups of patients.   
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Figure 9:  Initial Immunohistochemistry for CD4+ T cells.  The top figure includes all patients. 
Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who underwent an 
ablation procedure prior to nephrectomy (n=16) , distant  refers to ablation to the kidney 
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed 
by later nephrectomy (n=13).   The bottom figure includes patients who had ablation followed by 
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4). 
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared 
to control.  ns = non-significant, * = p<0.05. 
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Figure 10:  Initial Immunohistochemistry for CD8+ T cells.  The top figure includes all patients. 
Control refers to nephrectomy alone (n=9) , Treatment refers to any patient who underwent an 
ablation procedure prior to nephrectomy (n=16) , distant  refers to ablation to the kidney 
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed 
by later nephrectomy (n=13).   The bottom figure includes patients who had ablation followed by 
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4). 
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared 
to control.  ns = non-significant, * = p<0.05. 
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Figure 11: Initial Immunohistochemistry for CD45RO+ T cells.  The top figure includes all 
patients. Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who 
underwent an ablation procedure prior to nephrectomy (n=16) , distant  refers to ablation to the 
kidney followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ 
followed by later nephrectomy (n=13).   The bottom figure includes patients who had ablation 
followed by nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), 
local (n=4). Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group 
compared to control.  ns = non-significant, * = p<0.05. 
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Figure 12: Initial Immunohistochemistry for FoxP3+ cells.  The top figure includes all patients. 
Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who underwent an 
ablation procedure prior to nephrectomy (n=16) , distant  refers to ablation to the kidney 
followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ followed 
by later nephrectomy (n=13).   The bottom figure includes patients who had ablation followed by 
nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), local (n=4). 
Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group compared 
to control.  ns = non-significant, * = p<0.05. 
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Figure 13: Initial Immunohistochemistry for Granzyme B+ cells.  The top figure includes all 
patients. Control refers to nephrectomy alone (n=9) , Ablation refers to any patient who 
underwent an ablation procedure prior to nephrectomy (n=16) , distant  refers to ablation to the 
kidney followed by nephrectomy at a later date (n=3), local refers to ablation of a distant organ 
followed by later nephrectomy (n=13).   The bottom figure includes patients who had ablation 
followed by nephrectomy within 1 year: control (n=9), treatment (ablation) (n=7), distant (n=3), 
local (n=4). Kruskal Wallis test is top line, Dunn’s multiple comparisons test between each group 
compared to control.  ns = non-significant, * = p<0.05. 
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Figure 14: Initial Immunohistochemistry for KP1+ cells, which represents a stain for 
macrophages.  The top figure includes all patients. Control refers to nephrectomy alone (n=9) , 
Ablation refers to any patient who underwent an ablation procedure prior to nephrectomy (n=16), 
distant  refers to ablation to the kidney followed by nephrectomy at a later date (n=3), local refers 
to ablation of a distant organ followed by later nephrectomy (n=13).   The bottom figure includes 
patients who had ablation followed by nephrectomy within 1 year: control (n=9), treatment 
(ablation) (n=7), distant (n=3), local (n=4). Kruskal Wallis test is top line, Dunn’s multiple 
comparisons test between each group compared to control.  ns = non-significant, * = p<0.05. 
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Figure 15: Updated IHC using new immunotherapy platform protocol.  Density N refers to 
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.  
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients 
who received ablation procedure prior to nephrectomy.  Groups are compared with student t test.  
CD3 T cell marker, CD4 subset of T cells, CD8 subset of T cells, CD45RO a stain for a subset of 
T cell memory cells.  
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Figure 16: Updated IHC using new immunotherapy platform protocol.  Density N refers to 
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.  
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients 
who received ablation procedure prior to nephrectomy.  Groups are compared with student t test.  
CD20 B cell stain, CD68 macrophage stain, FoxP3 stain for regulatory subset, Gr-B granzyme B 
for cytotoxic cells. 
50 
 
 
Figure 17: Updated IHC using new immunotherapy platform protocol.  Density N refers to 
normal kidney tissue, Density IM refer to invasive margin, Density CT refers to center of tumor.  
Controls refers to patients who received nephrectomy alone, ablation refers to group of patients 
who received ablation procedure prior to nephrectomy.  Groups are compared with student t test.  
PD-1 program death receptor 1, PD-L1 programmed death receptor ligand 1 expressing immune 
cells, PD-L1 program death receptor ligand 1 expressing tumor cells, and PD-L1 H score.  
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Flow cytommetry 
 Figures 18 through 32 represent the flow cytommetry analysis for patients analyzed 
prospectively after ablation to a primary renal cell carcinoma in the kidney.  Day 0 (D0) reflects 
a baseline blood draw prior to ablation procedure and could occur within a one month period 
prior to the procedure.  Day 1 (D1) reflects the immediate day following procedure while the 
patient remained hospitalized.  Day 28 (D28) is the blood draw obtained 4 weeks following 
procedure at a scheduled return visit with urology.  Day 180 is the blood draw obtained at 6 
months following the ablation procedure.  Several patients had a blood draw at 4 months and 1 
year following the procedure without the 6 month blood draw.  These blood draws were 
excluded from the analysis.  In each of the figures, A represents the gating used for flow 
cytommetry.  B represents all patients with baseline (day 0), day 1, day 28, and day 180 blood 
draws with percentage of positive cells.  Kruskal-Wallis (unmatched data) and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  C represents patients who had 
all four scheduled blood draws, and D represents individual patients with 3 blood draws at 
baseline, day 1, and day 28.   For both C and D, Friedman’s test (matched data at each time 
point) and Dunn’s multiple comparisons tests were used to determine statistical significance.   
CD4+T cells (Figure 18), CD8+T cells (Figure 19), CD19+B cells (Figure 20), CD4+ICOShi T 
cells (Figure 21), CD8+ICOShi T cells (Figure 22), CD4+CD45RO+T cells (Figure 28), lin-
CD4+CD45RO+CD62L+CCR7-  T cells representing T effector memory (Figure 29), lin-
CD4+CD45RO+CD62L+CCR7+  T cells representing T central memory (Figure 30), macrophage 
(Figure 31), and myeloid derived suppressor cells (Figure 32) did not show significant 
differences between baseline and later time points.  The regulatory immune subsets included 
CD4+FoxP3+ T cells (Figure 23), CD8+FoxP3+ T cells (Figure 24), CD4+CD25+FoxP3+ T cells 
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(Figure 25), CD4+CD25+Lap+ T cells (Figure 26), and CD4+CD25+CD127-T cells(Figure 27).  
The CD4+FoxP3+ T cells did show a statistically significant change between groups and a 
statistically significant increase between the day 1 blood draw that returned almost to baseline by 
the day 28 blood draw.  Similarly, CD4+CD25+Lap+ T cells showed a statistically significant 
change between groups and a statistically significant increase between the day 1 blood draw that 
returned almost to baseline by the day 28 blood draw.  Both the CD4+CD25+FoxP3+ T cells and 
the CD4+CD25+CD127- T cells had similar trends that approached, but did not reach 
significance.   
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Figure 18 Flow cytommetry analysis CD4+ T cells:  A represents the gating used for flow 
cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, 
day 28, and day 180 blood draws with percentage of positive CD4+ T cells.  Kruskall-Wallis and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  C represents 
patients who had blood draws at 4 time points, and D represents individual patients with 3 blood 
draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  (ns = not significant, * = 
p<0.05) 
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Figure 19 Flow cytommetry analysis CD8+ T cells:  A represents the gating used for flow 
cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, 
day 28, and day 180 blood draws with percentage of positive CD8+ T cells.  Kruskall-Wallis and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  C represents 
patients who had blood draws at 4 time points, and D represents individual patients with 3 blood 
draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  (ns = not significant, * = 
p<0.05)  
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Figure 20 Flow cytommetry analysis CD19+ B cells:  A represents the gating used for flow 
cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, 
day 28, and day 180 blood draws with percentage of positive CD19+ B cells.  Kruskall-Wallis 
and Dunn’s multiple comparisons tests were used to determine statistical significance.  C 
represents patients who had blood draws at 4 time points, and D represents individual patients 
with 3 blood draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = not 
significant, * = p<0.05) 
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Figure 21 Flow cytommetry analysis CD4+ ICOShi T cells:  A represents the gating used for 
flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 
1, day 28, and day 180 blood draws with percentage of positive CD4+ ICOShi  T cells.  Kruskall-
Wallis and Dunn’s multiple comparisons tests were used to determine statistical significance.  C 
represents patients who had blood draws at 4 time points, and D represents individual patients 
with 3 blood draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = not 
significant, * = p<0.05) 
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Figure 22 Flow cytommetry analysis CD8+ ICOShi T cells:  A represents the gating used for 
flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 
1, day 28, and day 180 blood draws with percentage of positive CD8+ ICOShi T cells.  Kruskall-
Wallis and Dunn’s multiple comparisons tests were used to determine statistical significance.  C 
represents patients who had blood draws at 4 time points, and D represents individual patients 
with 3 blood draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = not 
significant, * = p<0.05) 
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Figure 23: Flow cytommetry analysis CD4+ FoxP3+ T cells:  A represents the gating used for 
flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 
1, day 28, and day 180 blood draws with percentage of positive CD4+ FoxP3+ T cells.  Kruskall-
Wallis and Dunn’s multiple comparisons tests were used to determine statistical significance.  C 
represents patients who had blood draws at 4 time points, and D represents individual patients 
with 3 blood draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = not 
significant, * = p<0.05) 
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Figure 24 Flow cytommetry analysis CD8+ FoxP3+ T cells Figure:  A represents the gating used 
for flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), 
day 1, day 28, and day 180 blood draws with percentage of positive CD8+ FoxP3+ T cells.  
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  C represents patients who had blood draws at 4 time points, and D represents 
individual patients with 3 blood draws at baseline, day 1, and day 28.   For both C and D, 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 25 Flow cytommetry analysis CD4+ CD25+ FoxP3+ T cells:  A represents the gating used 
for flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), 
day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+ FoxP3+ T 
cells.  Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  C represents patients who had blood draws at 4 time points, and D represents 
individual patients with 3 blood draws at baseline, day 1, and day 28.   For both C and D, 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 26 Flow cytommetry analysis CD4+ CD25+ Lap+ T cells:  A represents the gating used 
for flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), 
day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+ Lap+ T cells.  
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  C represents patients who had blood draws at 4 time points, and D represents 
individual patients with 3 blood draws at baseline, day 1, and day 28.   For both C and D, 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, p<0.05)  
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Figure 27 Flow cytommetry analysis CD4+ CD25+ CD127 - T cells:  A represents the gating 
used for flow cytommetry, samples tested in triplicate.  B represents all patients with baseline 
(day 0), day 1, day 28, and day 180 blood draws with percentage of positive CD4+ CD25+ 
CD127 - T cells.  Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine 
statistical significance.  C represents patients who had blood draws at 4 time points, and D 
represents individual patients with 3 blood draws at baseline, day 1, and day 28.   For both C and 
D, Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 28 Flow cytommetry analysis CD4+ CD45RO+ Tcells:  A represents the gating used for 
flow cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 
1, day 28, and day 180 blood draws with percentage of positive CD4+ CD45RO+ T cells.  
Kruskall-Wallis and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  C represents patients who had blood draws at 4 time points, and D represents 
individual patients with 3 blood draws at baseline, day 1, and day 28.   For both C and D, 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 29 Flow cytommetry analysis TEM (T Effector Memory) lin-
CD4+CD45RO+CD62L+CCR7-  T cells:  A represents the gating used for flow cytommetry, 
samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, day 28, and 
day 180 blood draws with percentage of positive TEM T cells.  Kruskall-Wallis and Dunn’s 
multiple comparisons tests were used to determine statistical significance.  C represents patients 
who had blood draws at 4 time points, and D represents individual patients with 3 blood draws at 
baseline, day 1, and day 28.   For both C and D, Friedman’s test and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  (ns = not significant, * = 
p<0.05) 
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Figure 30 Flow cytommetry analysis TCM (T Central Memory) lin-
CD4+CD45RO+CD62L+CCR7+T cells:  A represents the gating used for flow cytommetry, 
samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, day 28, and 
day 180 blood draws with percentage of positive TCM cells.  Kruskall-Wallis and Dunn’s 
multiple comparisons tests were used to determine statistical significance.  C represents patients 
who had 4 time point blood draws, and D represents individual patients with 3 blood draws at 
baseline, day 1, and day 28.   For both C and D, Friedman’s test and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  (ns = not significant, * = 
p<0.05) 
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Figure 31 Macrophage:  A represents the gating used for flow cytommetry, samples tested in 
triplicate.  B represents all patients with baseline (day 0), day 1, day 28, and day 180 blood draws 
with percentage of positive CD4+ T cells.  Kruskall-Wallis and Dunn’s multiple comparisons 
tests were used to determine statistical significance.  C represents patients who had blood draws 
at 4 time points, and D represents individual patients with 3 blood draws at baseline, day 1, and 
day 28.   For both C and D, Friedman’s test and Dunn’s multiple comparisons tests were used to 
determine statistical significance.  (ns = not significant, * = p<0.05) 
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Figure 32 MDSC (Myeloid derived suppressor cells):  A represents the gating used for flow 
cytommetry, samples tested in triplicate.  B represents all patients with baseline (day 0), day 1, 
day 28, and day 180 blood draws with percentage of positive CD4+ T cells.  Kruskall-Wallis and 
Dunn’s multiple comparisons tests were used to determine statistical significance.  C represents 
patients who had 4 time point blood draws, and D represents individual patients with 3 blood 
draws at baseline, day 1, and day 28.   For both C and D, Friedman’s test and Dunn’s multiple 
comparisons tests were used to determine statistical significance.  (ns = not significant, * = 
p<0.05) 
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Cytokine Studies 
 The results of serum cytokine studies are represented in Figures 33 through 43.  All 10 
cytokines were measured prospectively in pg/mL and displayed on the x-axis in Figure 33 with 
the mean cytokine level at three time points represented by three bar graphs.  The first bar 
represents day 0 or baseline, the second bar represents 24 hours or day 1 following the ablation, 
the third bar represents day 28 after the ablation.   IL-6 was the cytokine that exhibited the 
highest levels in the serum at each time point and did exhibit statistically significant change from 
baseline to day 1.  Figure 34-43 show 7 patients who had matched baseline, 24 hour, and 28 day 
blood draws.  The most significant change was in IL-6 with a significant increase between 
baseline and day 1 based on the Dunn’s multiple comparison test.  The group difference based on 
the Kruskal Wallis test of IL-6 approached significance with p=0.052.  IL-10 did show a 
significant difference between groups using the Friedman test with a trend downward from 
baseline to day 1 to day 28.  IL-12p70 also found a significant difference between day 1 and day 
28 and between groups.  However, the level of IL-12p70 detected in the serum was very low 
approaching the level of the first standard and the confidence to report this finding is small.     
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Figure 33: Post ablation levels of cytokines.  Each cytokine is represented with 3 bars, the first 
bar corresponds to the baseline blood draw, bar 2 is day 1 following procedure, bar 3 is day 28 
blood draw.   
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Figure 34: Serum interferon γ level at baseline (D0), day 1 (D1), and day 28 (D28).  Each 
patient is represented with a different colored symbol.  As each patient had 3 blood draws, the 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 35: Serum IL-12p70 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient 
is represented with a different colored symbol.  The Friedman’s test and Dunn’s multiple 
comparison tests were used to determine statistical  significance.  (ns = not significant, * = 
significant with p<0.05) 
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Figure 36: Serum IL-10 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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Figure 37: Serum IL-13 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.   
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Figure 38: Serum IL-17 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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Figure 39: Serum IL-2 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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Figure 40: Serum IL-4 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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Figure 41: Serum interferon γ level at baseline (D0), day 1 (D1), and day 28 (D28).  Each 
patient is represented with a different colored symbol.  As each patient had 3 blood draws, the 
Friedman’s test and Dunn’s multiple comparisons tests were used to determine statistical 
significance.  (ns = not significant, * = p<0.05) 
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Figure 42: Serum IL-6 level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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Figure 43: Serum TNF-α level at baseline (D0), day 1 (D1), and day 28 (D28).  Each patient is 
represented with a different colored symbol.  As each patient had 3 blood draws, the Friedman’s 
test and Dunn’s multiple comparisons tests were used to determine statistical significance.  (ns = 
not significant, * = p<0.05) 
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IV. Discussion 
 The hypothesis of thermal ablation procedures cause a significant local inflammatory 
response leading to an immunogenic gene signature that will be confirmed with detectable 
changes in immune cells identified in tissue with immunohistochemistry and in the peripheral 
circulation was not established in the studies presented above.  The first aim examining a 
retrospective cohort of patients treated with thermal ablation following nephrectomy compared 
to nephrectomy alone did appear to find an inflammatory, immunogenic signature.  However, 
finding the inflammatory, immunogenic signature required removal of one sample due to it 
having significant different properties than the rest and not meeting quality control metrics and 
our decision to exclude one patient treated with cryoablation leaving only three samples from 
two patients treated with radiofrequency ablation.  As a result, the confidence in these findings is 
limited despite the BUM modeling and the significance detected by extremely small p-values. 
Gene signatures have previously been proposed in melanoma implicating the importance of 
connectivity between the innate and adaptive immune response 58,59 60. 
 The upstream molecules found during the Ingenuity analysis are known mediators of 
inflammation including cytokines, chemokines, toll like receptors, members of the Janus 
Kinase/Signal Transducer and Activator of Transcription (JAK/Stat) signaling pathway.  
Triggering Receptor Expressed on Myeloid Cells 1 or TREM1 was found to have significant 
activation with a p value of (1.73E-09).  TREM1 is known to be expressed on neutrophils, 
monocytes, and platelets 61  62.  It has been found to be related by Bruton’s Tyrosine Kinase 
(BTK) and Non-T cell activation linker (NTAL) 63.  TREM1 has been described as playing an 
important role in human sepsis 64 62 and blunting both toll like receptor 4 and TREM1 has been 
associated with blunting of the sometimes lethal sepsis response in animal modeling.  TREM1 
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has been described to be an innate receptor for necrotic cell death a mechanism of cell death 
described in ablation procedures.  TREM1 could be further explored in animal models with 
ablation procedures to understand if blocking TREM1 signaling could augment any protective 
effect from ablation or disrupt connectivity between innate and adaptive immune signaling.   
Gene microarray analysis has exploded in the field of oncology.  Given the amount of 
information generated from a study, generating a clinically meaningful signature that is 
duplicated by other data sets is challenging.  Some of the initial work in gene microarray analysis 
was carried out by Takahashi et al and published in 2001 65.  In this work, two distinct signatures 
were identified that clearly segregated patients into good and poor prognostic categories.  In a 
study by Kosari et al. gene microarray could clearly distinguish normal tissue adjuvant to renal 
carcinoma, indolent and aggressive biology tumors.  The microarray analysis was validated using 
quantitative reverse transcription-PCR (RT-PCR)  66.  One of the lead candidate genes to 
discriminate survival was the aptly named gene survivin.  In our datasets, survivin was not 
significant.  In 2005, Subramanian proposed using gene expression enrichment analysis to focus 
on gene sets to help interpret the results of the large amount of data emerging from genomic 
analysis  67.  Using this approach Maruschke et al. found 16 significantly upregulated or 
downregulated gene sets that were capable of differentiating high grade from low grade clear cell 
renal cell carcinomas 68.  More recently, molecular signatures known as ccA and ccB have been 
proposed and were validated in The Cancer Genome Atlas (TCGA) in clear cell renal cell 
carcinoma 69 70.   In our analysis, the biologic processes, pathways, and individual genes were all 
dominated by the immune system.  If the inflammation and immunogenicity can be harnessed to 
prime the immune system prior to additional immune based therapy as has been found in animal 
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modeling with melanoma and prostate cancer, this could rapidly be brought to clinic and 
potentially be explored in a wide variety of tumor types.   
 The second aim of the project was to determine in a retrospective cohort of patients if 
there is a correlation between the gene signature produced with thermal ablation followed by 
nephrectomy with changes detected in immunohistochemistry for specific immune cell subsets, 
comparing to patients treated with nephrectomy alone.  Based on our available analysis, we were 
unable to correlate the findings of our gene signature with differences in immune infiltrate 
between the two groups of patients studied.  
Interpreting the results of the immunohistochemistry retrospectively is challenging.  First 
considering patients who underwent a renal ablation followed later by nephrectomy, there was a 
wide range in time between the two procedures.  Will an ablation procedure have lasting immune 
impact six years after performed?  Will an ablation procedure have a local impact on the immune 
system 2 months after procedure?  These studies are difficult to perform prospectively in this 
patient population as the purpose of treating with ablative procedures is to provide definitive 
local control.  As a result, patients who receive a partial or radical nephrectomy in this context 
are viewed as local treatment failure of the RFA or cryoablation.  The exception to this role 
would be patients who have multiple masses and require subsequent surgery for a growing 
alternative mass as can often be the case in patients with Von Hippel Lindau or other instances in 
hereditary causes of multiple complex renal masses/cysts.  In the case of a solitary renal lesion, 
cryoablation and RFA are known to have local control rates approaching 90% and have been 
reported in single series to be greater than 95% in renal tumors less than 3cm 71.  As a result, the 
studies of our patients may reflect a more aggressive or different local biology than seen in 
typical series of solitary small renal tumors.  Also the impact of immune infiltration may be 
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significantly different in a patient who has local disease under control versus a patient who has 
failed previous ablation procedure.   
 Also adding a layer of complexity is that retrospective data has emerged in regards to the 
local and systemic immunity being vastly different in the context of higher staged and more 
aggressive tumor biology.  As a result, drawing conclusions from patients with largely T1a or 
T1b tumors and extrapolating to patients with locally advanced or metastatic disease is likely to 
be flawed.  In 2003, Bromwich et al. noted that patients with increased CD4+T cells within their 
tumor at the time of surgery had worse survival which was found to hold independent prognostic 
influence on multivariable analysis and was important regardless of tumor grade 72. Similar 
findings by Nakano et al, when analyzing 221 patients treated with primary nephrectomy for 
renal cell carcinoma where both increased CD4+ and CD8+ T cell infiltrates correlated with 
shortened survival, more advanced stage and tumor grade 73.   In a study by Cozar et al, looking 
at both the tumor infiltrating lymphocyte (TIL) population and peripheral blood immune cells in 
patients with RCC undergoing nephrectomy, increasing stage was associated with diminished 
TIL presence of NK cells, lower populations of effector memory cells which were characterized 
as CCR5/CXCR3/CD4+ cells, and an increased population of CD25+CD4+ cells consistent with a 
Treg population 74.  In a study of 70 patients with RCC undergoing nephrectomy, 16 patients had 
matched peripheral blood and TIL.  The authors observed high levels of the chemokine receptors 
CCR5, CXCR3, and CXCR6 on TILS corresponding to chemokines expressed in renal cell 
tissue.  Also observed where higher Treg populations with these chemokine receptors in the TIL 
population leading to a proposed mechanism of recruitment of these cells into the tumors for 
immune escape 75.   
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As increased understanding of important T cell subsets has expanded across research 
fields, additional studies have found that increased levels of regulatory T cell subsets defined by 
both flow cytommetry, IHC, and confirmed with functional assays has found a correlation 
between the presence of T regulatory cells and outcome in patients with renal cell carcinoma 76.   
In a large series from the Mayo clinic, the presence of CD4+CD25+FoxP3+ tumor infiltrating 
cells was not associated with poor outcome, but the presence of CD4+CD25+FoxP3- tumor 
infiltrating cells was associated with poor prognosis 77.   
The increased presence of Treg population in TIL population has been associated with 
worsening survival in patients treated with cytokine based immunotherapy 78,79.  Jensen et al. 
analyzed the TIL population in patients treated with high dose interleukin-2 treatment and found 
patients who had significant increases in Treg TIL after IL-2 therapy had worse survival and the 
only long term survivors observed on study were those who had low baseline Treg population 
and only a modest rise in Treg population following IL-2 therapy.  Griffiths found a higher 
population of Treg cells in circulation as compared to normal donors and an inferior survival in 
patients with RCC with elevated levels of Treg cells. 78 
In our analysis of the immunohistochemistry data, limited differences were found in 
immune cell staining between patients treated with nephrectomy alone or ablation followed by 
nephrectomy.  It is unclear if this is a function of both populations having active tumor at the 
time of resection, significant lag between ablation and nephrectomy, or lack of power given 
small sample size.    Interestingly, a difference was detected in PD-1 staining in the IM, however 
this does appear to be influenced by one patient who had significantly higher levels than both 
control and other treated tumor analyzed.   
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 The third and final aim of the project was to determine in a prospective cohort of patients 
if thermal ablation produces detectable changes in peripheral blood immune cell subsets and 
cytokine levels that can be detected over one day, four weeks, and a 6 month timeframe.   In a 
similar fashion as in our retrospective immunohistochemistry studies, the inflammatory gene 
signature was not confirmed in cytokine or flow cytommetry studies.  The only potential 
exceptions were subtle changes noted in potential T regulatory cell populations and early trends 
in serum cytokine levels of IL-6 and IL-10. 
In the flow cytommetry portion of our study, the most interesting observations occurred 
within the potential T regulatory (Treg) populations.  However, defining the Treg population in 
this setting is limited and challenging without the additional functional assays.  In a seminal 
work in 1995, Sakaguchi et al. identified CD4 cells expressing the IL-2 receptor alpha-chain 
(CD25) were crucial in protecting against auto-immunity and in graft rejection in mice 80.  
Further work by this group found that depletion of CD4+CD25high lead to tumor rejection in mice 
81.  The CD4+CD25high cells population when depleted and transferred into other mice can 
produce autoimmune disease 82 Work by Baecher-Allen et al. further characterized human 
CD4+CD25high population of T cells finding they were capable of suppressing other effector T 
cells, were resistant to activation, but were capable of being activated when plated with anti-CD3 
antibody with CD28 cross-linking which resulted in loss of regulatory function.  Importantly, 
when these cells were co-cultured with monoclonal antibodies directed against immune check 
point inhibitors CTLA-4, PD-1, and PD-L1, the CD4+CD25high continued to have regulatory 
function 83.  The identification of FoxP3 expression in T regulatory cells was reported by Hori et 
al in mice and Walker et al. in humans in 2003 84 85.  In humans, Walker found that peripheral 
CD4+CD25- T cells were capable of being induced to express FoxP3, which differed from mice. 
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Once induced, these cells were capable of suppressing other effector T cells through direct 
contact, which was not dependent on cytokine.     Work by Chen et al. found that in addition to 
Treg cells produced in the thymus, peripheral CD4+CD25- could be induced to become Treg 
cells under the influence of transforming growth factor beta (TGF-β) and T cell receptor (TCR) 
stimulation.  In addition FoxP3 could be induced under the influence of TGF-β 86.   Yagi et al. 
went on to show that human peripheral T cell CD4+CD25- transduced to express FoxP3 went on 
to up-regulate CTLA-4 and CD25 and exhibited Treg phenotype 87.  Findings by Morgan et al, 
questioned the expression of FoxP3 as a marker of regulatory T cells only as FoxP3 mRNA 
could be detected in all T cell clones and stimulated cells expressing FoxP3 were capable of 
producing interferon gamma and proliferation consistent with effector T cell population 88 .  Qiao 
et al. further identified the role of CD4+CD25+FoxP3+ T cells labeled as natural T regulatory 
cells  or nTregs by co-culturing with CD4+CD25- cells with IL-4 and anti-CD3 was capable of 
inducing a population of cells that were labeled as induced T regulatory cells or iTregs that did 
not express FoxP3 89.  Using a RAG 2-/- murine model that has no naturally occurring 
CD4+CD25+ T cells, daily peptide vaccine resulted in a significant population of 
CD4+CD25+FoxP3+ T cells with suppressive function 90.    
The accurate identification of a human T regulatory cell is challenging.  Part of the 
limitation revolves around the processing of cells required to identify the intracellular marker 
FoxP3.  Due to the need to permeabilize the cell surface, once stained for FoxP3, functional 
assays are not possible.  The combination of dendritic cell vaccine and low dose interleukin-2 
resulted in nearly immediate rise in CD4+CD25highFoxP3+ T cells 91 as detected in peripheral 
blood, which reduced after 8 days but did not return to baseline.  In patients with metastatic 
melanoma and metastatic RCC treated with high dose interleukin 2 therapy, patients who 
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achieved sustained response had diminished levels of Treg cells detected in peripheral blood 
following therapy, with those who had progressive disease had the opposite trend 92.   van der 
Vliet et al. reported high dose IL-2 diminished peripheral dendritic cell subsets, NK cells, while 
increasing CD4(+)CD25(+) T cells, which included the CD4(+)Foxp3(+) T cell subset 93.  
However, interestingly the CD4+CD25+ T cells were less capable of regulating other T cells as 
compared to freshly harvested CD4+CD25+ T cells. 
A different marker of Treg cells CD4+CD25+CD117- has been suggested by several 
groups.  However in work done in Dr. Sharma’s laboratory, patients treated with anti-CTLA-4 
based immune therapy that had cells with the surface markers CD4+CD25+CD117- did not have 
discriminatory function between T effector and T regulatory cells 94.  In this work, 
CD4+CD25+Lap+ cells were found to accurately identify a subset of T regulatory cells as 
determined by in vitro functional assays from cells taken from human subjects treated on a 
clinical trial.  Other groups have suggested using FoxP3 promoter methylation status as a way of 
accurately identifying Treg cells in human studies 95  96. 
  In our prospective analysis of circulating serum cytokines, interleukin-6 (IL-6) was the 
highest at baseline and significantly increased after ablation therapy.  Elevated IL-6 levels have 
been associated with poor outcome in mRCC treated with high dose IL-2 97.  Compared to 
healthy controls, Yoshida et al. reported IL-6 levels increase with increasing tumor stage and 
grade and is significantly elevated in patients with metastatic disease98.  In addition, TNF-α 
levels were elevated compared to controls, but not increase in a stage or grade dependence as 
witnessed with IL-6.  In a large multicenter trial evaluating IL-2 and IFN-α, elevated levels of 
IL-6 were associated with inferior survival 99.  Guida et al. compared serum cytokines and C-
reactive protein in healthy controls and patients with mRCC treated with subcutaneous IL-2 both 
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at baseline and during treatment 100.  C-reactive protein, IL-6, IL-8 were all significantly higher 
in patients with mRCC compared to healthy controls and greater elevation was associated with 
poor outcome.  Conversely, elevated IL-12 levels were associated with improved outcome.  On 
multivariate analysis, only CRP and IL-12 maintained significance.   Using baseline cytokine, 
circulating angiogenic factors, and the Memorial Sloan Kettering risk grouping, an improved 
prognostic risk score could be established to predict patients who would survive five years with 
mRCC 101.  The cytokines included IL-12p40, IL-6, and IL-5. 
 The changes found in the gene microarray portion of the study serve as a potential 
fingerprint indicating a locally immunogenic environment created by an ablation procedure.  
IHC was unable to capture significant differences in immune cell populations, but the 
retrospective analysis and the cohort of patients selected, progression of tumor after ablation and 
differing times between procedure and nephrectomy, likely did not serve as a representative 
patient population to detect such changes.  Significant changes were also not noted in peripheral 
blood immune cell subtypes by flow cytommetry and serum cytokine analysis.  However, the 
time frame of collecting these blood draws one day following the procedure, one month, and six 
months likely are not the optimal time to analyze for changes in either the innate or adaptive 
immune response.  To have ideally studied this question, an increased patient population would 
be required.  Nephrectomy or biopsy would occur within weeks or short months following the 
ablation.  Timed blood draws at baseline, day1, week 1, week 2, week 4, and then at month 3 and 
month 6 would be collected in all patients.  Unfortunately having patients undergo this degree of 
blood testing is likely not reasonable in this setting.   
 The above study was completed to help us analyze changes both within tissue and in the 
blood of patients treated with ablation in anticipation of an upcoming trial pairing cryoablation 
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with tremelimumab (anti-CTLA-4 antibody) in patients with metastatic renal cell carcinoma.  As 
the study does not contain a cryoablation only arm, our group wanted to better define changes 
related to ablation alone to help with interpretation of data from the trial.  The use of 
combination immunotherapy is underway in a variety of malignancies.  Ablation procedures may 
serve as a way to prime the immune system to better pair with immune check point blockade.   
V. Conclusions: 
 Thermal ablation changes the immune microenvironment as detected by gene microarray.  
These changes could not be confirmed by immunohistochemistry or in peripheral blood studies 
using flow cytommetry and cytokine analysis.  However, small sample sizes, early staged 
clinical disease, and the potential selection of a subset of patients with aggressive biology could 
have impacted our findings.  Understanding the impact of cryoablation or radiofrequency alone 
will be important in interpretation of clinical trial information in future studies.   
VI. Limitations 
 The limitations in this analysis are numerous.  The tissue collected was performed on a 
retrospective basis leading to the potential for sample collection bias.  Tumor tissue was 
collected predominately from early stage RCC patients, but several patients who developed 
metastatic disease were included leading to significant differences in the patient population.  
Ideally, limiting the patient selection to early stage localized disease would have helped 
interpretation of results.  Also significant differences in time between tissue acquisition and 
staining occurred, allowing for the potential for batch effects.  In the clinical trial of 
tremelimumab plus cryoablation versus tremelimumab alone, samples will be analyzed rapidly 
reducing the risk of batch effects.  In the gene microarray analysis, out of the five post treatment 
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samples submitted for analysis, one was deemed a significant outlier and was excluded and one 
was eventually excluded due to being a different procedure.  As a result only three samples 
remained, of which two were from the same patient potentially biasing the information obtained.  
Also, differences related to immune cell infiltration and in percentage of stroma versus tumor 
cells in each sample are not characterized and have the potential to lead to significant differences 
given such limited samples. In future analysis, having additional control sample biopsies from 
multiple sites of the same tumor may help control for these differences and lead to more 
confidence in interpreting the results.  In the cytokine studies, significant differences in sample 
storage time existed.  In a study by de Jager et al, storage time leads to cytokine degradation 
potentially impacting the results of our study 102.   
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